Tag: GLP-1
GLP-1 Drugs Linked to Lower Violent Behaviour in Rutgers Study
Rutgers University researchers found an association between GLP-1 receptor agonists (Ozempic, Wegovy) and weakened impulsivity-violence links in observational analysis. The…
Beyond GLP-1 drugs: Why obesity care requires more than medication
GLP-1 medications like semaglutide and tirzepatide have transformed obesity treatment, yet leading specialists warn that medication alone is insufficient. Sustainable…
GLP-1 Weight Loss Drugs Linked to Reduced Physical Activity Despite Weight Loss Success
New research analyzing Fitbit data reveals that people taking GLP-1 weight loss drugs experience declining physical activity levels despite successful…
Weekly semaglutide outperforms dulaglutide for diabetes control in UK primary care study
Large UK study shows weekly semaglutide provides superior blood sugar control and weight loss compared to dulaglutide in type 2…
Survodutide Weekly Injection Shows 17.5% Weight Loss in Phase 3 Obesity Trial
Phase 3 trial shows survodutide weekly injection achieved 17.5% weight loss versus 1.2% placebo in over 3,400 adults with obesity.…
GLP-1 Drugs Show 30% Lower Breast Cancer Risk in Major Study
Large observational study finds women taking GLP-1 drugs like Ozempic and Wegovy show 30% lower breast cancer rates. Clinical trials…
Oral GLP-1 Drug Achieves 11.3% Weight Loss in Phase 2 Trial
Phase 2b trial shows oral GLP-1 drug aleniglipron achieved 11.3% weight loss in 230 adults with obesity. Results suggest oral…
GLP-1 Weight-Loss Drugs Reduce Breast Cancer Risk by 17% in Largest Study to Date
New research from ASCO 2026 shows GLP-1 weight-loss medications reduce breast cancer risk by 17% and cancer mortality by 24%…